239 related articles for article (PubMed ID: 33849933)
1. GLP-1 Receptor Agonists in Diabetic Kidney Disease.
Michos ED; Tuttle KR
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1578-1580. PubMed ID: 33849933
[No Abstract] [Full Text] [Related]
2. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
3. Effects of Diabetes Medications Targeting the Incretin System on the Kidney.
MacIsaac RJ; Thomas MC
Clin J Am Soc Nephrol; 2018 Feb; 13(2):321-323. PubMed ID: 29321176
[No Abstract] [Full Text] [Related]
4. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
Hiramatsu T; Ito H; Okumura S; Asano Y; Iguchi D; Furuta S
Diab Vasc Dis Res; 2020; 17(6):1479164120971220. PubMed ID: 33371732
[TBL] [Abstract][Full Text] [Related]
5. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
Mann JFE; Fonseca VA; Poulter NR; Raz I; Idorn T; Rasmussen S; von Scholten BJ; Mosenzon O;
Clin J Am Soc Nephrol; 2020 Apr; 15(4):465-473. PubMed ID: 32132141
[TBL] [Abstract][Full Text] [Related]
6. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side.
Dieter BP; Alicic RZ; Tuttle KR
Am J Physiol Renal Physiol; 2018 Dec; 315(6):F1519-F1525. PubMed ID: 30110568
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and Management of Type 2 Diabetic Kidney Disease.
Doshi SM; Friedman AN
Clin J Am Soc Nephrol; 2017 Aug; 12(8):1366-1373. PubMed ID: 28280116
[TBL] [Abstract][Full Text] [Related]
9. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
[TBL] [Abstract][Full Text] [Related]
10. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
11. Diabetic Kidney Disease.
Tong L; Adler SG
Clin J Am Soc Nephrol; 2018 Feb; 13(2):335-338. PubMed ID: 29046291
[No Abstract] [Full Text] [Related]
12. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycaemia in patients with diabetes mellitus and renal impairment.
Hettige TS; Cooper ME
Diab Vasc Dis Res; 2017 Mar; 14(2):166-168. PubMed ID: 28128009
[No Abstract] [Full Text] [Related]
14. New anti-diabetic agents: major advances with unanswered questions.
Sabouret P; Bocchino PP; Biondi-Zoccai G
Rev Cardiovasc Med; 2020 Dec; 21(4):489-492. PubMed ID: 33387991
[TBL] [Abstract][Full Text] [Related]
15. Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients.
Kim MK; Kim DM
J Diabetes Investig; 2021 Jun; 12(6):914-916. PubMed ID: 33759351
[TBL] [Abstract][Full Text] [Related]
16. Annual deterioration of renal function in hypertensive patients with and without diabetes.
Polonia J; Azevedo A; Monte M; Silva JA; Bertoquini S
Vasc Health Risk Manag; 2017; 13():231-237. PubMed ID: 28721063
[TBL] [Abstract][Full Text] [Related]
17. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
Scheen AJ
Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes.
Heuvelman VD; Van Raalte DH; Smits MM
Cardiovasc Res; 2020 Apr; 116(5):916-930. PubMed ID: 31825468
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives.
Gurgle HE; White K; McAdam-Marx C
Vasc Health Risk Manag; 2016; 12():239-49. PubMed ID: 27350752
[TBL] [Abstract][Full Text] [Related]
20. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
